Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (megakaryocyte progenitors) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 1 stopped | 0.73 |
| literature PubMed | 46 Parkinson's papers of 3,111 | 0.49 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8109
Sealed predictions
- SPN in dopamine neurons, braak-0.16 (p 0.685) → -0.26 (p 0.493)receipt 8116
Swarm cases
receipt 8116: SPN in dopamine neurons, braak
- power
- full sample -0.22 (p 0.384, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.403, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.19 (p 0.455, n 18). could be the mix.
- skeptic
- leave-one-out range -0.40 to -0.13, sign flips 0; without severely affected donors -0.22 (p 0.384, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SPN in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts